Visual prognosis appears generally good after PPV for retained lens material

Article

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent pars plana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well.

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent pars plana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well, said Lawrence Y. Ho, MD.

Dr. Ho reported the findings from a retrospective review that included analyses for predictors of good and poor visual outcomes. The series included 166 consecutive cases from a 6-year period extending from January 2001 to January 2007. Follow-up exceeded 6 months in more than 80% of eyes. The visual results showed 72% of eyes achieved vision of 20/40 or better while only 10.8% ended up with vision of 20/200 or worse.

"The outcomes in this series surpass those in prior large series that showed only 58% of patients had vision of 20/40 or better while almost 18% saw 20/200 or worse. We believe improvements in both phaco technology and vitrectomy combined with earlier detection of treatment complications, such as CME with more widespread use of OCT, may account for the difference. However, this warrants further investigation," said Dr. Ho.

Predictors of vision outcomes were examined in a multivariate analysis. Better presenting vision, insertion of a posterior chamber IOL, and absence of preoperative eye disease were associated with a good vision outcome.

Development of glaucoma and presence of preexisting eye disease were associated with a poor vision outcome while anterior vitrectomy at the time of cataract surgery and sulcus lens placement at cataract surgery had protective value.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.